Using a cell therapy as a potential treatment for Parkinson’s with BlueRock's CEO
Agios on today’s phase 2 data for the pyruvate kinase activator mitapivat in sickle cell disease
The future of gene editing with Intellia’s CEO
Flagship’s small molecule play Empress emerges out of stealth mode
Big deals and small molecules with the CEO of Nimbus Therapeutics
OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO
Hopewell Therapeutics’ CEO on the company’s $25M raise and next-gen LNPs
Talking oncology targets (EGFR, FLT3, B7H4 and more) with Cullinan Oncology
Converting infused medicines into subcutaneous injections, including PD-1s, with Halozyme
Discussing the FIREFLY-1 pediatric low-grade glioma data with Day One Bio at #ASCO23
Making the case for allo durability at #ASCO23 with Allogene’s CEO
Modality profile: Radiotherapies at #ASCO23 with Dr. Phil Kantoff
Discussing the MIRASOL ovarian cancer data with Immunogen at #ASCO23
Antibody-drug conjugates at #ASCO23 with Seagen’s David Epstein
Biosimilars, toripalimab, and TIGIT with the CEO of Coherus.
Modality profile: Oncolytic Immunotherapies at #ASCO23
Dissecting the TIGIT battleground at #ASCO23
Modality profile: Bi-Specifics and cytokines at #ASCO23
BIO Chairman and Nkarta CEO talks biotech
BridgeBio's Neil Kumar on drug development
.png){kind=logo}
